R3HDM1 inhibitors are a class of chemical compounds designed to target and modulate the activity of the R3HDM1 protein. R3HDM1 is a member of a larger family of proteins that contain an R3H domain, which is known for its ability to bind nucleic acids. The inhibition of R3HDM1 activity can have significant effects on cellular processes, as this protein is involved in regulating gene expression and protein interactions. Structurally, inhibitors of R3HDM1 can vary widely, but they often share certain features that allow them to interact effectively with the R3H domain or other key sites of the R3HDM1 protein. These compounds typically engage in molecular interactions such as hydrogen bonding, hydrophobic interactions, or van der Waals forces to achieve a high degree of specificity for R3HDM1. By binding to this protein, the inhibitors can affect its ability to engage in its natural biological functions, often leading to altered cellular signaling pathways or changes in gene expression profiles.
Research on R3HDM1 inhibitors often involves detailed structure-activity relationship (SAR) studies to refine their binding affinity and selectivity. Structural modifications to the inhibitor molecules are explored to optimize the binding properties and potency against R3HDM1. Such studies provide insights into how different substituents on the inhibitor scaffold contribute to its activity and specificity. Analytical techniques like X-ray crystallography, molecular modeling, and in vitro biochemical assays are commonly used to assess the binding modes of these inhibitors to R3HDM1. The design and synthesis of R3HDM1 inhibitors also involve considerations for their stability, solubility, and bioavailability, which are essential factors for their functionality in experimental models. Although these compounds are primarily studied in biochemical and cellular contexts to understand their effects on R3HDM1-mediated pathways, their unique chemical properties and mechanism of action make them valuable tools for probing the biological roles of R3HDM1 and exploring the broader implications of R3H domain-containing proteins in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
An inhibitor of DNA methyltransferase, can lead to reduced methylation of DNA, potentially affecting gene expression including that of R3HDM1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor, can increase the levels of proteins by preventing their degradation, potentially including R3HDM1. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor, can alter chromatin structure and gene expression, potentially impacting R3HDM1 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, can affect various signaling pathways, potentially altering the regulation of proteins such as R3HDM1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, can modulate the p38 MAPK signaling pathway, potentially influencing R3HDM1 activity or expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, can affect the mTOR signaling pathway, potentially impacting protein synthesis and the regulation of proteins including R3HDM1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An ERK inhibitor, can interfere with the MAPK/ERK pathway, potentially affecting the regulation of R3HDM1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, can alter the JNK signaling pathway, potentially modifying the regulation or activity of R3HDM1. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
An Hsp90 inhibitor, can disrupt client protein stabilization, potentially affecting the stability and function of R3HDM1. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
An MDM2 antagonist, can stabilize p53 and modulate p53-dependent gene expression, potentially affecting R3HDM1. | ||||||